TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Dementia Home Care Project: a Randomised Controlled Trial to Evaluate the Effectiveness of a Home Care Program for Supporting Caregivers of Persons With Dementia in Developing Countries: a Randomised Controlled Trial From Goa, India
Brief Summary: The aim of this trial was to apply a home based, flexible, stepped-care intervention designed to improve the awareness and knowledge of family caregivers regarding dementia, to maximise their caregiving resources and to improve their caregiving skills. A Randomized Controlled Trial (RCT) will be used to evaluate the same wherein the intervention group will get the services immediately and the control arm would receive the same after a period of 6 months.


Options:
A: Arm Label: Specialist; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychotherapy | Arm Label: Enhanced Usual Care; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): Enhanced Usual Care, Specialist
B: Arm Label: Depression Care; Type: EXPERIMENTAL; Interventions: Combination Product: evidence-based depression treatment | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: COMBINATION_PRODUCT; Name: evidence-based depression treatment; Assigned to Arm(s): Depression Care
C: Arm Label: Wait List Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Trauma Focused Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Trauma Focused Cognitive Behavioral Therapy; Assigned to Arm(s): Intervention Group
D: Arm Label: Home Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home based, flexible, stepped care intervention | Arm Label: Wait-list; Type: OTHER; Interventions: Behavioral: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period. | Intervention Type: BEHAVIORAL; Name: Home based, flexible, stepped care intervention; Assigned to Arm(s): Home Care | Intervention Type: BEHAVIORAL; Name: Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.; Assigned to Arm(s): Wait-list

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.
Brief Summary: This is a 12-Week clinical trial in patients with Primary hypercholesterolemia or mixed dyslipidemia to study the effects of ER niacin/laropiprant on lipids.


Options:
A: Intervention Type: DRUG; Name: niacin (+) laropiprant (+) simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: niacin (+) laropiprant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: simvastatin; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: OTHER; Interventions: Drug: niacin (+) laropiprant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: simvastatin, Drug: Comparator: atorvastatin calcium | Intervention Type: DRUG; Name: Comparator: simvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: niacin (+) laropiprant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: atorvastatin calcium; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Niacin Extended-Release and simvastatin Tablets; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Extended-Release Niacin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Extended-Release Niacin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-centre, Randomised, Double-blind Comparison of Intravenous Dexmedetomidine With Propofol for Continuous Sedation of Ventilated Patients in Intensive Care Unit
Brief Summary: Patients in the ICU who need help with their breathing are put onto a machine called a ventilator and are also given a medicine, called a sedative, which helps them to sleep and makes them more comfortable. Propofol is a sedative that is routinely used for these purposes.

For most patients the aim of sedation is to make them sleepy but still able to respond to nursing staff (light sedation).

Dexmedetomidine is a new sedative for use in intensive care and in this clinical study,dexmedetomidine is compared to propofol. It is thought that dexmedetomidine might be slightly better at allowing patients to be sleepy but still respond to people around them. It also does not appear to affect patient's breathing. The purpose of this study is to test whether dexmedetomidine really does have these advantages compared to propofol.

In this study, we hope to show that: dexmedetomidine is at least as good as propofol in helping patients to sleep better and making them more comfortable, and that they are able to communicate and cooperate better with the staff treating them, and that patients treated with dexmedetomidine require a shorter time on the ventilator than those treated with propofol.


Options:
A: Arm Label: Balanced Anesthesia; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: NoNarc TIVA; Type: ACTIVE_COMPARATOR; Interventions: Drug: TIVA NoNarc | Intervention Type: DRUG; Name: TIVA NoNarc; Assigned to Arm(s): NoNarc TIVA
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: NaCl 9/00 | Arm Label: dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: dexmedetomidine | Intervention Type: DRUG; Name: NaCl 9/00; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: dexmedetomidine; Assigned to Arm(s): dexmedetomidine
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Multi-centre, Randomised, Double-blind Comparison of Intravenous Dexmedetomidine With Propofol for Continuous Sedation of Ventilated Patients in Intensive Care Unit
Brief Summary: Patients in the ICU who need help with their breathing are put onto a machine called a ventilator and are also given a medicine, called a sedative, which helps them to sleep and makes them more comfortable. Propofol is a sedative that is routinely used for these purposes.

For most patients the aim of sedation is to make them sleepy but still able to respond to nursing staff (light sedation).

Dexmedetomidine is a new sedative for use in intensive care and in this clinical study,dexmedetomidine is compared to propofol. It is thought that dexmedetomidine might be slightly better at allowing patients to be sleepy but still respond to people around them. It also does not appear to affect patient's breathing. The purpose of this study is to test whether dexmedetomidine really does have these advantages compared to propofol.

In this study, we hope to show that: dexmedetomidine is at least as good as propofol in helping patients to sleep better and making them more comfortable, and that they are able to communicate and cooperate better with the staff treating them, and that patients treated with dexmedetomidine require a shorter time on the ventilator than those treated with propofol.


Options:
A: Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): Midazolam | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine
B: Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): 2
D: Arm Label: Dexmedetomidine; Type: EXPERIMENTAL; Interventions: Drug: Dexmedetomidine HCL Injection | Arm Label: Midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam Injection | Intervention Type: DRUG; Name: Dexmedetomidine HCL Injection; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Midazolam Injection; Assigned to Arm(s): Midazolam

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised, Double-blind, Double-dummy, 52-week, Parallel Group Study of a Standard Dosing Regimen With Salmeterol/Fluticasone propionate50/250 Twice Daily Diskus Versus a Symptom-driven, Variable Dosing Regimen With Formoterol/Budesonide Combination 4.5/160 in Adult Asthmatics
Brief Summary: To compare a stable dose of salmeterol/fluticasone propionate with a variable dose of formoterol/budesonide where the dose is adjusted according to a physician-guided self-management plan


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol (Symbicort) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone/salmeterol (Advair) | Intervention Type: DRUG; Name: budesonide/formoterol (Symbicort); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: fluticasone/salmeterol (Advair); Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Budesonide/formoterol Turbuhaler; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Salmeterol/fluticasone Diskus; Assigned to Arm(s): N/A
C: Arm Label: Flutiform 250/10 micrograms; Type: EXPERIMENTAL; Interventions: Drug: Flutiform 250/10 micrograms | Arm Label: Flutiform 50/5 micrograms; Type: EXPERIMENTAL; Interventions: Drug: Flutiform 50/5 micrograms | Arm Label: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms | Arm Label: Flixotide pMDI 250 micrograms; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flixotide pMDI 250 micrograms | Intervention Type: DRUG; Name: Flutiform 250/10 micrograms; Assigned to Arm(s): Flutiform 250/10 micrograms | Intervention Type: DRUG; Name: Flutiform 50/5 micrograms; Assigned to Arm(s): Flutiform 50/5 micrograms | Intervention Type: DRUG; Name: Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms; Assigned to Arm(s): Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms | Intervention Type: DRUG; Name: Flixotide pMDI 250 micrograms; Assigned to Arm(s): Flixotide pMDI 250 micrograms
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Salmeterol/fluticasone propionate or formoterol/budesonide | Intervention Type: DRUG; Name: Salmeterol/fluticasone propionate or formoterol/budesonide; Assigned to Arm(s): Arm 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
Brief Summary: This study is a phase 2, randomized, double-blind, placebo controlled, multi-center study to estimate the improvement in PFS (compared to control subjects) and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel in the treatment of subjects with advanced recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Primary Outcome Measure:

• Progression free survival (PFS)

Secondary Outcome Measures:

* Object Response Rate (ORR), duration of response (DOR). CA-125 response rate
* Safety and Tolerability
* Change and duration of change on blood levels of CA-125


Options:
A: Arm Label: pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): placebo
B: Arm Label: Pazopanib/Paclitaxel association; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Drug: Paclitaxel | Arm Label: Paclitaxel alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib/Paclitaxel association | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel alone, Pazopanib/Paclitaxel association
C: Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD 40mg/m2 ivgtt q4w | Arm Label: PLD + Apatinib; Type: EXPERIMENTAL; Interventions: Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd; Assigned to Arm(s): PLD + Apatinib | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w; Assigned to Arm(s): PLD
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: Arm C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B, Arm C | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Arm C

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development of a Programme to Show the Positive Effect of a Nutritional Programme on Preventing Functional and Weight Losses in Patients With Dementia
Brief Summary: The main objective of this study is the improvement of the quality of life and state of health of elderly people with cognitive deterioration and their families through a weight loss prevention programme.

The secondary objectives are the improvement of the state of nutrition, a reduction in the use of resources and a reduction in the burden on the main carer.


Options:
A: Intervention Type: BEHAVIORAL; Name: Nutritional programme; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: dl-alpha-tocopherol, Drug: Memantine | Arm Label: Arm 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: dl-alpha-tocopherol; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 4
C: Arm Label: 1.; Type: EXPERIMENTAL; Interventions: Drug: DHA (Docosahexaenoic Acid) | Arm Label: 2.; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DHA (Docosahexaenoic Acid); Assigned to Arm(s): 1. | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2.
D: Intervention Type: DRUG; Name: EPAX 1050TG; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Development of a Programme to Show the Positive Effect of a Nutritional Programme on Preventing Functional and Weight Losses in Patients With Dementia
Brief Summary: The main objective of this study is the improvement of the quality of life and state of health of elderly people with cognitive deterioration and their families through a weight loss prevention programme.

The secondary objectives are the improvement of the state of nutrition, a reduction in the use of resources and a reduction in the burden on the main carer.


Options:
A: Intervention Type: PROCEDURE; Name: family style dinner; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Nutritional programme; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: "brain preservation' diet | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: "brain preservation' diet; Assigned to Arm(s): 1
D: Arm Label: usual mealtime care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: mealtime assistance; Type: EXPERIMENTAL; Interventions: Other: trained volunteer mealtime assistance | Intervention Type: OTHER; Name: trained volunteer mealtime assistance; Assigned to Arm(s): mealtime assistance

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Brief Summary: The purpose of this clinical trial is to demonstrate the benefit of the immunotherapeutic product GSK1572932A when given to patients with Non-Small Cell Lung Cancer, after removal of their tumor. A course of 13 injections will be administered over 27 months. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: GSK1572932 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo Control | Intervention Type: BIOLOGICAL; Name: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Assigned to Arm(s): GSK1572932 Group | Intervention Type: BIOLOGICAL; Name: Placebo Control; Assigned to Arm(s): Placebo Group
B: Arm Label: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Arm Label: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Biological: autologous dendritic cell adenovirus CCL21 vaccine | Intervention Type: BIOLOGICAL; Name: autologous dendritic cell adenovirus CCL21 vaccine; Assigned to Arm(s): Arm 1
D: Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Biological: Tecemotide, Drug: Single low dose cyclophosphamide, Other: Best Supportive Care (BSC) | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Saline, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: Tecemotide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Control Arm, Investigational Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-Term Post- War Adjustment in Bosnian Adolescents, Their Parents and Teachers
Brief Summary: Context: This is the first multi-site randomized controlled study of the effectiveness of a group treatment for war-exposed adolescents delivered in-country within a public school system.

Objective: To evaluate the effectiveness of a trauma/grief-focused group treatment program in reducing symptoms of posttraumatic stress disorder (PTSD), depression, and traumatic grief in war-exposed Bosnian youths attending 10 secondary schools located in Central Bosnia.


Options:
A: Intervention Type: BEHAVIORAL; Name: Trauma and Grief Component Therapy for Adolescents (Group Version); Assigned to Arm(s): N/A
B: Arm Label: Assessment only; Type: ACTIVE_COMPARATOR; Interventions: Other: Assessment | Arm Label: Fostering Healthy Futures (FHF) Assessment + FHF; Type: EXPERIMENTAL; Interventions: Other: Assessment, Behavioral: Fostering Healthy Futures (FHF) | Intervention Type: OTHER; Name: Assessment; Assigned to Arm(s): Assessment only, Fostering Healthy Futures (FHF) Assessment + FHF | Intervention Type: BEHAVIORAL; Name: Fostering Healthy Futures (FHF); Assigned to Arm(s): Fostering Healthy Futures (FHF) Assessment + FHF
C: Arm Label: Coping Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Coach | Arm Label: Coping Coach Waitlist Control; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Coach | Intervention Type: BEHAVIORAL; Name: Coping Coach; Assigned to Arm(s): Coping Coach, Coping Coach Waitlist Control
D: Arm Label: Child, Parenting, & Parent Web-Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Bounce Back Now Website | Arm Label: Child & Parenting Web-Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Bounce Back Now Website | Arm Label: Child & Parent Web-based Assessment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Bounce Back Now Website; Assigned to Arm(s): Child & Parenting Web-Intervention, Child, Parenting, & Parent Web-Intervention

Answer: A